SBH
BCRX icon

Segall Bryant & Hamill’s BioCryst Pharmaceuticals BCRX Stock Holding History

Segall Bryant & Hamill’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,134,813
Closed -$8.61M – 580
2025
Q3 		$8.61M Sell
1,134,813
-85,264
-7% -$710K 0.11% 256
2025
Q2 		$10.9M Sell
1,220,077
-110,237
-8% -$1.03M 0.15% 214
2025
Q1 		$9.98M Sell
1,330,314
-91,882
-6% -$741K 0.15% 216
2024
Q4 		$10.7M Sell
1,422,196
-68,180
-5% -$518K 0.15% 213
2024
Q3 		$11.3M Sell
1,490,376
-36,105
-2% -$274K 0.15% 206
2024
Q2 		$9.43M Sell
1,526,481
-222,967
-13% -$1.23M 0.17% 200
2024
Q1 		$8.89M Buy
1,749,448
+10,131
+0.6% +$57K 0.17% 211
2023
Q4 		$10.4M Sell
1,739,317
-278,669
-14% -$1.61M 0.2% 180
2023
Q3 		$14.3M Sell
2,017,986
-19,702
-1% -$142K 0.17% 164
2023
Q2 		$14.3M Buy
2,037,688
+199,834
+11% +$1.6M 0.15% 180
2023
Q1 		$15.3M Buy
1,837,854
+168,855
+10% +$1.63M 0.17% 167
2022
Q4 		$19.2M Sell
1,668,999
-12,190
-0.7% -$152K 0.21% 139
2022
Q3 		$21.2M Sell
1,681,189
-142,020
-8% -$1.83M 0.25% 116
2022
Q2 		$19.3M Buy
1,823,209
+879,417
+93% +$9.07M 0.22% 130
2022
Q1 		$15.3M Buy
+943,792
New +$15.1M 0.15% 166

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Segall Bryant & Hamill's BCRX Position: Q4 2025 in Review

Segall Bryant & Hamill sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 1,134,813 shares — an estimated $8.61M sold.

Segall Bryant & Hamill first reported a position in BCRX in Q1 2022 and held it in 15 quarters. The position peaked at $21.2M in Q3 2022. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Segall Bryant & Hamill reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 1,134,813 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $8.61M.
  • Segall Bryant & Hamill first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 15 quarters.
  • Segall Bryant & Hamill's BioCryst Pharmaceuticals position peaked at $21.2M in Q3 2022.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Segall Bryant & Hamill's 13F filing for Q4 2025, filed 13 Feb 2026.